Skip to main content
OpenTrials
Completed

NCT Number: NCT07724379

A Study of Tetanus Antibody of Healthy Adults

The goal of this observational study is to learn about antibody level of tetanus of adults in high-income city of china. The main question it aims to answer is:

1. Analysis of tetanus antibody distribution across different age groups 2. Evaluation of the TQS method for determining antibody status 3. Correlation between primary vaccination history and tetanus antibody concentrations Blood samples were voluntarily provided by adult healthy participants for tetanus antibody analysis over a continuous collection period of more than one year.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Tetanus Bacterial Infections Bacterial Infections and Mycoses Clostridium Infections Gram-Positive Bacterial Infections Infections

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Peking University First Hospital

Beijing, Beijing Municipality, 100034, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Voluntarily sign the informed consent form；
  • Be aged 18 years or older；
  • Be willing to provide a blood sample for biochemical testing

Exclusion criteria

  • Receipt of immunoglobulin, blood, or blood products within 6 months prior to enrollment；
  • Refusal to provide tetanus vaccination history (including vaccination records, CDC vaccine administration registry, or subject's recall)；
  • Individuals with recent tetanus vaccination (within 5 years), acute illness, pregnancy, or immunosuppressive conditions will be excluded

Treatment and study plan

Primary outcomes

  1. Tetanus Antibody Level

    Time frame: Baseline (single blood draw at enrollment)

    Single blood draw

Secondary outcomes

  1. tetanus antibody level by TQS/mTQS method

    Time frame: Baseline (single blood draw at enrollment)

    at baseline

Sponsors and collaborators

Lead sponsor

Peking University First Hospital

Other

Registry information

Official study title

A Prospective Study of Tetanus Antibody Protective Efficacy in Healthy Populations in Beijing

Acronym: tetanus

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jul 24, 2026
Registry last updated
Jul 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.